Comparison of the Effect of Topiramate and Sodium Valporate in Migraine Prevention: A Randomized Blinded Crossover Study

Shaygannejad, Vahid; Janghorbani, Mohsen; Ghorbani, Abbas; Ashtary, Fereshteh; Zakizade, Naser; Nasr, Vida

doi:10.1111/j.1526-4610.2006.00413.x

Cited by 74 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two additional Class I studies report topiramate is as effective as propranolol 16 or sodium valproate, 17 drugs previously established as effective for migraine prevention. In the first study, subjects given topiramate 50 mg/day had reduced mean migraine frequency (episodes/month) from baseline (6.07 Ϯ In a crossover Class I trial (2-month washout between therapies) comparing topiramate 50 mg/day with sodium valproate 400 mg/day, both groups showed improvement from baseline in headache frequency, intensity, and duration.…”

mentioning

confidence: 99%

“…In the first study, subjects given topiramate 50 mg/day had reduced mean migraine frequency (episodes/month) from baseline (6.07 Ϯ In a crossover Class I trial (2-month washout between therapies) comparing topiramate 50 mg/day with sodium valproate 400 mg/day, both groups showed improvement from baseline in headache frequency, intensity, and duration. 17 Average monthly migraine frequency decreased by 1.8 times with sodium valproate (baseline 5.4 Ϯ 2.5; posttreatment 3.6 Ϯ 2.1; CI 1.0 -2.6; p Ͻ 0.001), as compared with a 3-time reduction with topiramate (baseline 5.4 Ϯ 2.0; posttreatment 2.4 Ϯ 2.4; CI 2.1-3.9; p Ͻ 0.001). Headache intensity decreased by 3.7 with sodium valproate (baseline 7.7 Ϯ 1.2; treatment 4.0 Ϯ 2.1; CI 2.9 -4.6; p Ͻ 0.001), as compared with a reduction of 3.6 with topiramate (baseline 6.9 Ϯ 1.2, treatment phase 3.3 Ϯ 1.5; CI 2.9 -4.3; p Ͻ 0.001).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

et al. 2012

View full text Add to dashboard Cite

Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention? Methods:The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention. Results and Recommendations:The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A). Neurology Epidemiologic studies suggest approximately 38% of migraineurs need preventive therapy, but only 3%-13% currently use it.1 In 2000, the American Academy of Neurology (AAN) published guidelines for migraine prevention.2,3 Since then, new clinical studies have been published on the efficacy and safety of migraine preventive therapies. This guideline seeks to assess this new evidence to answer the following clinical question: For patients with migraine, which pharmacologic therapies are proven effective for prevention, as measured by reduced migraine attack frequency, reduced number of migraine days, or reduced attack severity? This article addresses the safety and efficacy of pharmacologic therapies for migraine prevention.Separate guidelines are available for botulinum toxin. 4 The 2008 guideline included a Level B recommendation that botulinum toxin was probably ineffective for treatment of episodic migraine. A new guideline is in development. An updated guideline on nonsteroidal anti-inflammatory drugs 5 and complementary alternative treatments has been approved for publication as a companion to this guideline. 5 DESCRIPTION OF THE ANALYTIC PROCESSThe AAN and the American Headache Society participated in the development process. An author panel of headache and methodologic experts was assembled to review the evidence. Computerized searches of the MEDLINE, PsycINFO, and CINAHL databases identified new studies (published in English). The search strategy used the MeSH term "headache" (exploded) and a published search strategy for identifying randomized controlled trials ( Appendices e-1-e-5, reference e1, and tables e-1 and e-2 are available on the Neurology Web site at www.neurology.org.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Other studies have shown that TPM at 100 mg/day is effective in prevention of migraine headache, and in reducing the severity of the attack. [28][29][30] Results of electrophysiological evaluation by P300 show no statistical differences either at the first or at the third month. At the first month, latencies were increased in frontal (from 320-326) and central (from 307-322) areas but these increases did not achieve statistical significance.…”

Section: Discussionmentioning

confidence: 91%

Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients

Kececi¹,

Atakay²

2009

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…Consistent with this view, several agonists at GABA receptors have been used as prophylactic antimigraine drugs. In this context, valproate (Cutrer et al 1997a;Shaygannejad et al 2006), baclofen in a small open study (Hering-Hanit 1999), and gabapentin (Di Trapani et al 2000) may prevent migraine attacks, while valproate has also been suggested to be effective in the acute treatment of migraine in another small open trial (Mathew et al 2000). Despite the above clinical evidence, it should be kept in mind that not all of the aforementioned compounds are selective in their action at GABA receptors, and the mechanisms involved in their antimigraine effect remain unclear.…”

Section: Gaba Receptorsmentioning

confidence: 99%

Current and prospective pharmacological targets in relation to antimigraine action

Mehrotra

Gupta

Chan

et al. 2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

Migraine is a recurrent incapacitating neurovascular disorder characterized by unilateral and throbbing headaches associated with photophobia, phonophobia, nausea, and vomiting. Current specific drugs used in the acute treatment of migraine interact with vascular receptors, a fact that has raised concerns about their cardiovascular safety. In the past, α-adrenoceptor agonists (ergotamine, dihydroergotamine, isometheptene) were used. The last two decades have witnessed the advent of 5-HT 1B/1D receptor agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute treatment of migraine. Moreover, current prophylactic treatments of migraine include 5-HT 2 receptor antagonists, Ca 2+ channel blockers, and β-adrenoceptor antagonists. Despite the progress in migraine research and in view of its complex etiology, this disease still remains underdiagnosed, and available therapies are underused. In this review, we have discussed pharmacological targets in migraine, with special emphasis on compounds acting on 5-HT (5-HT 1-7 ), adrenergic (α 1 , α 2, and β), calcitonin gene-related peptide (CGRP 1 and CGRP 2 ), adenosine (A 1 , A 2 , and A 3 ), glutamate (NMDA, AMPA, kainate, and metabotropic), dopamine, endothelin, and female hormone (estrogen and progesterone) receptors. In addition, we have considered some other targets, including gamma-aminobutyric acid, angiotensin, bradykinin, histamine, and ionotropic receptors, in relation to antimigraine therapy. Finally, the cardiovascular safety of current and prospective antimigraine therapies is touched upon.

show abstract

Comparison of the Effect of Topiramate and Sodium Valporate in Migraine Prevention: A Randomized Blinded Crossover Study

Cited by 74 publications

References 25 publications

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients

Current and prospective pharmacological targets in relation to antimigraine action

Contact Info

Product

Resources

About